Research ExplorerPublicationsDoes histologic subtype affect oncologic outcomes after neph...

Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?

Standard

Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? / Crépel, Maxime; Isbarn, Hendrik; Capitanio, Umberto; Liberman, Daniel; Jeldres, Claudio; Sun, Maxine; Shariat, Shahrokh F; Widmer, Hugues; Arjane, Philippe; Graefen, Markus; Montorsi, Francesco; Patard, Jean-Jacques; Perrotte, Paul; Karakiewicz, Pierre I.

In: UROLOGY, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Crépel, M, Isbarn, H, Capitanio, U, Liberman, D, Jeldres, C, Sun, M, Shariat, SF, Widmer, H, Arjane, P, Graefen, M, Montorsi, F, Patard, J-J, Perrotte, P & Karakiewicz, PI 2009, 'Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?', UROLOGY. <http://www.ncbi.nlm.nih.gov/pubmed/19628262?dopt=Citation>

APA

Crépel, M., Isbarn, H., Capitanio, U., Liberman, D., Jeldres, C., Sun, M., Shariat, S. F., Widmer, H., Arjane, P., Graefen, M., Montorsi, F., Patard, J-J., Perrotte, P., & Karakiewicz, P. I. (2009). Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? UROLOGY. http://www.ncbi.nlm.nih.gov/pubmed/19628262?dopt=Citation

Vancouver

Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M et al. Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? UROLOGY. 2009.

Bibtex

@article{136a41aa69b643698f37d4d38dbaa88c,
title = "Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?",
abstract = "OBJECTIVES: To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. METHODS: We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. RESULTS: At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. CONCLUSIONS: Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.",
author = "Maxime Cr{\'e}pel and Hendrik Isbarn and Umberto Capitanio and Daniel Liberman and Claudio Jeldres and Maxine Sun and Shariat, {Shahrokh F} and Hugues Widmer and Philippe Arjane and Markus Graefen and Francesco Montorsi and Jean-Jacques Patard and Paul Perrotte and Karakiewicz, {Pierre I}",
year = "2009",
language = "Deutsch",
journal = "UROLOGY",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?

AU - Crépel, Maxime

AU - Isbarn, Hendrik

AU - Capitanio, Umberto

AU - Liberman, Daniel

AU - Jeldres, Claudio

AU - Sun, Maxine

AU - Shariat, Shahrokh F

AU - Widmer, Hugues

AU - Arjane, Philippe

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Patard, Jean-Jacques

AU - Perrotte, Paul

AU - Karakiewicz, Pierre I

PY - 2009

Y1 - 2009

N2 - OBJECTIVES: To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. METHODS: We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. RESULTS: At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. CONCLUSIONS: Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.

AB - OBJECTIVES: To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS. METHODS: We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries. RESULTS: At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS. CONCLUSIONS: Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.

M3 - SCORING: Zeitschriftenaufsatz

JO - UROLOGY

JF - UROLOGY

SN - 0090-4295

ER -